Skip to main content
Log in

Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1

  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

Glucagon-like peptide-1 (GLP-1) is attracting increasing interest on account of its prominent benefits in type 2 diabetes. However, its clinical application is limited because of short biological half-life. This study was designed to produce a C-terminal site-specific PEGylated analog of cysteine-mutated GLP-1 (cGLP-1) to prolong its action. The gene of cGLP-1 was inserted into pET32a to construct a thioredoxinA fusion protein. After expression in BL21 (DE3) strain, the fusion protein was purified with Ni-affinity chromatography and then was PEGylated with methoxy-polyethylene glycol-maleimide (mPEG10K-MAL). The PEGylated fusion protein was purified with anion exchange chromatography and then was cleaved by enterokinase. The digested product was further purified with reverse-phase chromatography. Finally, 8.7 mg mPEG10K–cGLP-1 with a purity of up to 98% was obtained from the original 500 ml culture. The circular dichroism spectra indicated that mPEG10K–cGLP-1 maintained the secondary structure of native GLP-1. As compared with that of native GLP-1, the plasma glucose lowering activity of mPEG10K–cGLP-1 was significantly extended. These results suggest that our method will be useful in obtaining a large quantity of mPEG10K–cGLP-1 for further study and mPEG10K–cGLP-1 might find a role in the therapy of type 2 diabetes through C-terminal site-specific PEGylation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Drucker, D. J. (1998). Diabetes, 47, 159–169.

    Article  CAS  Google Scholar 

  2. Qualmann, C., Nauck, M. A., Holst, J. J., et al. (1995). Acta Diabetologica, 32, 13–16.

    Article  CAS  Google Scholar 

  3. Turton, M. D., O'shea, D., Gunn, I., et al. (1996). Nature, 379, 69–72.

    Article  CAS  Google Scholar 

  4. Flint, A., Raben, A., Astrup, A., et al. (1998). Journal of Clinical Investigation, 101, 515–520.

    Article  CAS  Google Scholar 

  5. Nauck, M. A., & Meier, J. J. (2005). Regulatory Peptides, 128, 135–148.

    Article  CAS  Google Scholar 

  6. Pauly, R. P., Rosche, F., Wermann, M., et al. (1996). Journal of Biological Chemistry, 271, 23222–23229.

    Article  CAS  Google Scholar 

  7. Vilsboll, T., Agerso, H., Krarup, T., et al. (2003). Journal of Clinical Endocrinology and Metabolism, 88, 220–224.

    Article  CAS  Google Scholar 

  8. Dou, W. F., Lei, J. Y., Zhang, L. F., et al. (2008). Protein Expression and Purification, 61, 45–49.

    Article  CAS  Google Scholar 

  9. Lee, S. H., Lee, S., Youn, Y. S., et al. (2005). Bioconjugate Chemistry, 16, 377–382.

    Article  Google Scholar 

  10. Siegel, E. G., Gallwitz, B., Scharf, G., et al. (1999). Regulatory Peptide, 79, 93–102.

    Article  CAS  Google Scholar 

  11. Zhang, Z. Z., Yang, S. S., Dou, H., et al. (2004). Protein Expression and Purification, 36, 292–299.

    Article  CAS  Google Scholar 

  12. Mitsuda, Y., Takimoto, A., Kamitani, S., et al. (2002). Protein Expression and Purification, 25, 448–455.

    Article  CAS  Google Scholar 

  13. Kingsley, G. R., & Getchell, G. (1960). Clinical Chemistry, 6, 466–475.

    CAS  Google Scholar 

  14. Burcelin, R., Dolci, W., & Thorens, B. (1999). Metabolism, 48, 252–258.

    Article  CAS  Google Scholar 

  15. Deacon, C. F., Knudsen, L. B., Madsen, K., et al. (1998). Diabetologia, 41, 271–278.

    Article  CAS  Google Scholar 

  16. Zhou, L., Zhao, Z., Li, B., et al. (2008). Protein Expression and Purification, 64, 225–230.

    Article  Google Scholar 

  17. Mehrnejad, F., Naderi-Manesh, H., Ranjbar, B., et al. (2008). Applied Biochemistry and Biotechnology, 149, 109–118.

    Article  CAS  Google Scholar 

  18. Wang, J. H., Tam, S. C., Huang, H., et al. (2004). Biochemical and Biophysical Research Communications, 317, 965–971.

    Article  CAS  Google Scholar 

  19. Long, D. L., Doherty, D. H., Eisenberg, S. P., et al. (2006). Experimental Hematology, 34, 697–704.

    Article  CAS  Google Scholar 

  20. Veronese, F. M., Mero, A., Caboi, F., et al. (2007). Bioconjugate Chemistry, 18, 1824–1830.

    Article  CAS  Google Scholar 

  21. Yamamoto, Y., Tsutsumi, Y., Yoshioka, Y., et al. (2003). Nature Biotechnology, 21, 546–552.

    Article  CAS  Google Scholar 

  22. Sato, H. (2002). Advanced Drug Delivery Reviews, 54, 487–504.

    Article  CAS  Google Scholar 

  23. Deiters, A., Cropp, T. A., Summerer, D., et al. (2004). Bioorganic & Medicinal Chemistry Letters, 14, 5743–5745.

    Article  CAS  Google Scholar 

  24. Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., et al. (1994). Journal of Biological Chemistry, 269, 6275–6278.

    CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the China National Nature Science Foundation (30772679) and Hi-Tech Research and Development Program of China-863 Program (2007AA02Z101).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wenbing Yao.

Additional information

Mingming Gao and Hong Tian contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, M., Tian, H., Ma, C. et al. Expression, Purification, and C-terminal Site-Specific PEGylation of Cysteine-Mutated Glucagon-Like Peptide-1. Appl Biochem Biotechnol 162, 155–165 (2010). https://doi.org/10.1007/s12010-009-8725-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12010-009-8725-6

Keywords

Navigation